Overview

Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia

Status:
Recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of eltrombopag when added to r-ATG and CsA in treatment naive East-Asian adult and pediatric patients with SAA.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antilymphocyte Serum
Cyclosporine
Cyclosporins
Immunosuppressive Agents
Thymoglobulin